Managing mixed dyslipidemia in special populations

Preventive Cardiology

Volumn 13, Issue 2, 2010, Pages 78-83

  Miller, Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; AGE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ETHNICITY; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGE FACTORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; PREVALENCE; RISK FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 77952081218     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2009.00057.x     Document Type: Review

References (47)

1. U.S. Obesity Trends 1985-2006. Updated 2007. http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps, Accessed July 31, 2008
2. Prevalence of overweight and obesity among adults: United States, 1999-2002. Updated 2007. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99.htm, Accessed July 31, 2008
3. Després JP, Lemieux I, Bergeron J. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049.
4. Wild SH, Byrne CD. Risk factors for diabetes and coronary heart disease. BMJ 2006, 333:1009-1011.
5. Reichley KB, Mueller WH, Hanis CL. Centralized obesity and cardiovascular disease risk in Mexican Americans. Am J Epidemiol 1987, 125:373-386.
6. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004, 27:2444-2449.
7. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 17:3143-3421.
8. Zimmet PZ, Alberti KGMM. Introduction: Globalization and the non-communicable disease epidemic. Obesity (Silver Spring) 2006, 14:1-3.
9. http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm, Accessed July 31, 2008
10. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
11. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
12. Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
13. Miller M, Seidler A, Kwiterovich PO. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation 1992, 86:1165-1170.
14. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008, 101:1003-1008.
15. St-Pierre AC, Cantin B, Dagenais GR. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005, 25:553-559.
16. Bittner V. Perspectives on dyslipidemia and coronary heart disease in women. J Am Coll Cardiol 2005, 46:1628-1635.
17. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease disadvantage. Arch Intern Med 1995, 155:57-61.
18. Matthews KA, Meilahn E, Kuller LH. Menopause and risk factors for coronary heart disease. N Engl J Med 1989, 321:641-646.
19. Lakoski SG, Cushman M, Criqui M. Gender and C-reactive protein: data from the Multithnic Study of Atherosclerosis (MESA) cohort. Am Heart J 2006, 152:593-598.
20. O'Meara JG, Kardia SL, Armon JJ. Ethnic and sex differences in the prevalence, treatment and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004, 164:1313-1318.
21. Miller M, Byington R, Hunninghake D. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Arch Intern Med 2000, 160:343-347.
22. Bailey CJ, Campbell IW, Chan JCN. The role of metformin in polycystic ovary syndrome and infertility. Metformin. The Gold Standard 2007, 223-232. eds, In, Chichester, UK, John Wiley & Sons
23. Mosca L, Banka CL, Benjamin EJ. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007, 115:1481-1501.
24. Mosca L. Management of dyslipidemia in women in the post-hormone therapy era. J Gen Intern Med 2005, 20:297-305.
25. Ridker PM, Buring JE, Rifai N. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611-619.
26. Sacks FM, Bray GA, Carey VJ. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009, 360:859-873.
27. Miller M, Beach V, Sorkin JD. Comparative Effects of 3 Popular Diets on Lipids, Endothelial Function and C-Reactive Protein during Weight Maintenance. J Am Diet Assoc 2009, 109:713-718.
28. Cui Y, Blumenthal RS, Flaws JA. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001, 161:1413-1419.
29. Dudeja V, Misra A, Pandey RM. BMI does not accurately predict overweight in Asian Indians in northern India. Br J Nutr 2001, 86:105-112.
30. IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf, Accessed July 31, 2008
31. Williams RA, Flack JM, Gavin JR. Guidelines for management of high-risk African Americans with multiple cardiovascular risk factors: recommendations of an expert consensus panel. Ethn Dis 2007, 17:214-220.
32. Burchfiel CM, Skelton TN, Andrew ME. Metabolic syndrome and echocardiographic left ventricular mass in blacks; the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2005, 112:819-927.
33. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
34. Kullo IJ, Jan MF, Bailey KR. Ethnic differences in low-density lipoprotein particle size in hypertensive adults. J Clin Lipidol 2007, 1:218-224.
35. D'Agostino RB, Grundy S, Sullivan LM. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
36. Fincher C, Williams JE, MacLean V. Racial disparities in coronary heart disease: a sociological view of the medical literature on physician bias. Ethn Dis 2004, 14:360-371.
37. Butler J, Rodondi N, Zhu Y. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 2006, 47:1595-1602.
38. Alexander CM, Landsman PB, Teutsch SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210-1214.
39. Petersen KF, Befroy D, Dufour S. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142.
40. Kannel WB. Cardiovascular disease preventive measures for the older patient: an epidemiologic perspective. Am J Geriatr Cardiol 2006, 15:382-388.
41. Li C, Ford ES, Mokdad AH. Recent trends in waist circumference and waist-height ratio among US children and adolescents. Pediatrics 2006, 118:e1390-e1398.
42. Mattsson N, Rönnemaa T, Juonala M. The prevalence of the metabolic syndrome in young adults. The Cardiovascular Risk in Young Finns study. J Intern Med 2007, 261:159-169.
43. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk. An American Heart Association Scientific Statement from the Atherosclerosis, Hypertension and Obesity in the Young Committee. Circulation 2003, 107:1448-1453.
44. Kavey R-EW, Allada V, Daniels SR. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and the Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation 2006, 114:2710-2738.
45. Barter P, Gotto AM, LaRosa JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
46. Miller M, Cannon CP, Murphy SA. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730.
47. Keech AC, Mitchell P, Summanen PA. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.